Singapore markets close in 3 hours 41 minutes

Ocugen, Inc. (OCGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.06+0.16 (+2.32%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close6.90
Open6.89
Bid0.00 x 3100
Ask0.00 x 3100
Day's range6.84 - 7.30
52-week range0.25 - 18.77
Volume10,649,377
Avg. volume49,227,674
Market cap1.399B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.26
Earnings date12 Aug 2021 - 16 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.38
  • Why Ocugen Stock Rose, Then Slipped Today
    Motley Fool

    Why Ocugen Stock Rose, Then Slipped Today

    Noble Capital analyst Robert LeBoyer initiated coverage of the stock with an unhesitant outperform (i.e., buy) recommendation. Like many Ocugen bulls, LeBoyer is most excited about Covaxin. This is the coronavirus vaccine candidate currently being developed by Bharat Biotech, the American company's partner in India, in collaboration with the Indian Council of Medical Research-National Institute of Virology.

  • Yahoo Finance Video

    Ocugen CEO on vaccine hesitancy in the U.S.

    Ocugen CEO Shankar Musunuri and Yahoo Finance's Julie Hyman discuss a range of topics around the company's work on a COVID-19 vaccine as well as vaccine distribution and hesitancy.

  • Why Shares of Ocugen Climbed Today
    Motley Fool

    Why Shares of Ocugen Climbed Today

    Shares of biotech company Ocugen (NASDAQ: OCGN) jumped nearly 13% today as the latest COVID figures show a significant rise in cases, hospitalizations, and deaths -- especially among the unvaccinated. Over the last two weeks, COVID cases are up 140%, while hospitalizations and deaths are up by one-third. Ocugen has partnered with Bharat Biotech, the company responsible for Covaxin, the first COVID vaccine developed in India to receive emergency authorization.